GlaxoSmithKline will invest $139 million in its biopharmaceutical manufacturing site in Rockville, MD to support production of BENLYSTA (belimumab) for systemic lupus erythematosus (SLE). The Rockville site is also expected to house production of a new subcutaneous form of belimumab which is currently under FDA review.    The investment will provide additional internal capacity to increase bulk drug substance production by nearly 50% to respond to increased demand. Benlysta has grown at least ...